Ubiquigent and Forma Therapeutics have entered into a multi-year strategic research and development (R&D) collaboration agreement for the design and development of novel deubiquitylase (DUB) enzyme inhibitors.
Collaboration
Under the terms of the collaboration agreement, Ubiquigent will design novel DUB inhibitors and evaluate them using its biology platform. During this term, Forma will have exclusive access and an option for a worldwide licence to all compounds and associated data from Ubiquigent libraries generated under the partnership. Furthermore, Ubiquigent will work exclusively for the benefit of Forma on a specific defined number of DUB targets. An upfront payment with research support will be paid to Ubiquigent, which will also be eligible for possible additional milestones payments.
“We are extremely pleased to enter into our first collaboration agreement of this type,” commented Ubiquigent’s commercial director, Jason Mundin. “This agreement represents not only the next step in our relationship with Forma, but also validates our approach of combining targeted chemistry with a focused biology platform. We look forward to working more closely with our colleagues at Forma in this exciting field.”
“DUBs are an increasingly important family of drug targets for many therapeutic directions,” stated Chris Dinsmore, PhD, vice president and head of chemistry, Forma Therapeutics. “Combining Ubiquigent’s drug design talents and proven capabilities with Forma’s repertoire of DUB-targeting chemotypes, across various structurally and computationally elucidated binding modes, is an exciting discovery opportunity. With novel compounds and mechanism of action insights from this collaboration, we hope to accelerate our ongoing efforts to deliver differentiated medicines to patients in need.”
Ubiquigent is a specialist developer and supplier of drug discovery services, high quality research tools and chemistry to the life science research community worldwide.